Collectively, these results highlight the therapeutic potential of Tofacitinib, a JAK-STAT pathway inhibitor, and NAC, an antioxidant agent, in modulating aberrant immune responses and suppressing inflammatory cell infiltration in RA. This evidence concerns the gene SOAT1 and rheumatoid arthritis.